A Nashville-based startup just raised $125 million, crossed a $2 billion valuation, and is now spinning up an entirely new company to tackle everything broken about how America pays for and delivers cancer care. That startup is Thyme Care — and what founders built here is a masterclass in profitable, mission-driven growth.
According to CNBC, Thyme Care closed its Series E round led by Morgan Health, with strategic participation from Humana and CVS Health Ventures — two of the largest payers in the country — alongside a16z Bio + Health, AlleyCorp, and HealthQuest Capital. The deal values the company at more than $2 billion and brings total funding to well above $300 million.
But the number that actually matters here isn’t the valuation. It’s this: Thyme Care is profitable and generating positive free cash flow. In a funding environment where most late-stage health startups are burning capital to buy growth, that distinction is everything.
What This Actually Means
Thyme Care isn’t just raising money — it’s reorganizing. Co-founders Robin Shah and Bobby Green, M.D., announced the formation of Thyme Companies, a new parent entity designed to build an entire portfolio of businesses attacking different broken parts of the oncology ecosystem. Shah moves to Executive Chairman of Thyme Companies; Green stays as President and CMO of the flagship; and a new CEO, Brad Diephuis, M.D., takes the helm of Thyme Care’s core operations.
That’s not a startup raising a Series E. That’s a company building a platform. The difference is massive.
Thyme Care’s model works by coordinating patients, providers, and health plans around a shared cancer care approach. The company currently serves more than 10.5 million people across all 50 states and manages over $7 billion in oncology spending. Their validated data shows a 5-10% reduction in total cost of care — which, when you’re talking about oncology, translates to hundreds of millions of dollars in savings annually.
Payers noticed. When Humana and CVS Health Ventures write you a check, they’re not doing it because the deck looked nice. They’re doing it because they want access to the infrastructure you’ve built.
Compare this to the Fitbit founders, who returned to build another health tech company from scratch — or how Harvey built an $11 billion legal AI valuation by dominating a specialized vertical. The pattern is consistent: the startups reaching generational scale pick one high-stakes, underserved problem and refuse to let go until the data proves them right.
The Numbers Behind It
Thyme Care’s raise lands at an interesting moment for healthcare startups overall. With the company managing $7 billion in oncology spend and serving 10.5 million covered lives, the revenue-per-covered-life math starts to look compelling to any strategic buyer or IPO investor watching from the sidelines.
The round also signals something bigger happening in healthcare venture. According to Crunchbase, US startup funding reached $87 billion in Q1 2026 — and healthcare remains one of the top three sectors by deal volume. But smart capital in 2026 isn’t chasing growth-at-all-costs. It’s chasing profitable growth. Thyme Care checks that box.
The participation of Morgan Health (JPMorgan’s healthcare subsidiary), Humana, and CVS Health Ventures also tells you something about where payer-provider alignment is heading. These are the companies that pay out billions in cancer claims every year. Investing in a platform that provably reduces those costs by 5-10% isn’t charity — it’s a hedge.
Thyme Companies, the new parent org, plans to launch its first new business before the end of 2026, targeting biosimilar adoption and clinical trial enrollment — two areas where billions of dollars in healthcare value are lost every year due to slow adoption and patient access problems.
The Hustler’s Library Take
What Shah and Green did at Thyme Care is what every founder should study: they picked a problem that was undeniable (cancer patients have to coordinate their own care, often at the worst moment of their lives), built proof that their model worked, then used that proof to attract the most credible strategic partners in the space. Humana and CVS Health didn’t lead this round — they joined it. That’s what happens when your data speaks louder than your pitch deck.
The formation of Thyme Companies is the next level of that thinking. Instead of taking a profitable exit or expanding horizontally into adjacent health conditions, they’re going deeper into the problem they know better than anyone. That’s the same kind of focus that drove Emergent AI from zero to unicorn in under 18 months. The founders who win at the highest level don’t diversify early — they double down until their vertical is locked.
There’s also a lesson here for founders who aren’t building $2 billion companies. Most businesses already have access to the data they need to make their own case — whether that’s reduced customer churn, faster delivery times, or measurable cost savings for clients. The founders who raise capital (or close big customers) are the ones who figured out how to quantify what they already do.
What You Should Do
1. Find the metric that makes your case undeniable. Thyme Care didn’t raise on vision — they raised on “5-10% verified reduction in total cost of care.” If you’re not tracking a number that speaks for you, start now.
2. Pursue strategic investors, not just financial ones. Humana and CVS Health Ventures don’t just write checks — they open doors to millions of covered lives. Ask yourself who the equivalent strategic investor is in your space.
3. Profitability is a fundraising advantage, not a sign you’re thinking too small. Thyme Care is profitable. That’s the reason payers trusted them enough to invest. Being cash-flow positive gives you leverage, not limitations.
4. Think in platforms, not products. The move from Thyme Care to Thyme Companies is a signal about how the founders are thinking: not “what’s our one thing” but “what ecosystem can we own.” Once you’ve proven product-market fit, the next question is what adjacent problem your team is uniquely positioned to solve.
Source: CNBC | Additional reporting: Pulse 2.0
Want more breakdowns like this in your inbox? Join the Hustler’s Library for free and get the best business insights delivered straight to you.
Ready to Know Where You Stand?
The Business Journey dashboard maps your exact position across all 13 stages. Track your progress, unlock resources for each step, and build with a framework used by thousands of founders at Hustler's Library.
No credit card required · Takes 3 minutes · Personalized to your stage
